<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB01113</drugbank-id>
  <drugbank-id>APRD00628</drugbank-id>
  <drugbank-id>DB07725</drugbank-id>
  <name>Papaverine</name>
  <description>An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.</description>
  <cas-number>58-74-2</cas-number>
  <unii>DAA13NKG2Q</unii>
  <average-mass>339.385</average-mass>
  <monoisotopic-mass>339.147058165</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A1881</ref-id>
        <pubmed-id>15457029</pubmed-id>
        <citation>Tang Y, Luan J, Zhang X: Accelerating tissue expansion by application of topical papaverine cream. Plast Reconstr Surg. 2004 Oct;114(5):1166-9.</citation>
      </article>
      <article>
        <ref-id>A1883</ref-id>
        <pubmed-id>16159054</pubmed-id>
        <citation>Liu JK, Couldwell WT: Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2005;2(2):124-32.</citation>
      </article>
      <article>
        <ref-id>A1885</ref-id>
        <pubmed-id>15519189</pubmed-id>
        <citation>Takeuchi K, Sakamoto S, Nagayoshi Y, Nishizawa H, Matsubara J: Reactivity of the human internal thoracic artery to vasodilators in coronary artery bypass grafting. Eur J Cardiothorac Surg. 2004 Nov;26(5):956-9.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of impotence and vasospasms.</indication>
  <pharmacodynamics>Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries.</pharmacodynamics>
  <mechanism-of-action>Perhaps by its direct vasodilating action on cerebral blood vessels, Papaverine increases cerebral blood flow and decreases cerebral vascular resistance in normal subjects; oxygen consumption is unaltered. These effects may explain the benefit reported from the drug in cerebral vascular encephalopathy.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life>0.5-2 hours</half-life>
  <protein-binding>~90%</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.</description>
    <direct-parent>Benzylisoquinolines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Isoquinolines and derivatives</class>
    <subclass>Benzylisoquinolines</subclass>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Anisoles</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Dimethoxybenzenes</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenoxy compounds</alternative-parent>
    <alternative-parent>Pyridines and derivatives</alternative-parent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Anisole</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzylisoquinoline</substituent>
    <substituent>Dimethoxybenzene</substituent>
    <substituent>Ether</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Methoxybenzene</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>O-dimethoxybenzene</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenol ether</substituent>
    <substituent>Phenoxy compound</substituent>
    <substituent>Pyridine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000784</drugbank-id>
      <name>Papaverine codecarboxylate</name>
      <unii>3RX65N0VN7</unii>
      <cas-number>56896-69-6</cas-number>
      <inchikey>VTJFMXLVZKZSGE-UHFFFAOYSA-N</inchikey>
      <average-mass>586.5269</average-mass>
      <monoisotopic-mass>586.171631734</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT000412</drugbank-id>
      <name>Papaverine hydrochloride</name>
      <unii>23473EC6BQ</unii>
      <cas-number>61-25-6</cas-number>
      <inchikey>UOTMYNBWXDUBNX-UHFFFAOYSA-N</inchikey>
      <average-mass>375.846</average-mass>
      <monoisotopic-mass>375.123735904</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT002205</drugbank-id>
      <name>Papaverine sulfate</name>
      <unii>7A476JZB2T</unii>
      <cas-number>2053-26-1</cas-number>
      <inchikey>KYFCEOITJFJQGT-UHFFFAOYSA-N</inchikey>
      <average-mass>437.46</average-mass>
      <monoisotopic-mass>437.114437879</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="italian" coder="">Papaverina</synonym>
    <synonym language="english" coder="ban">Papaverine</synonym>
  </synonyms>
  <products>
    <product>
      <name>Papaverine Hydrochloride</name>
      <labeller>Claris Lifesciences, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>36000-015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on>2010-11-04</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Papaverine Hydrochloride</name>
      <labeller>Claris Lifesciences, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>36000-016</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on>2010-11-04</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Papaverine Hydrochloride</name>
      <labeller>Claris Lifesciences Limited</labeller>
      <ndc-id/>
      <ndc-product-code>68950-023</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on>2010-11-04</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Papaverine Hydrochloride</name>
      <labeller>Claris Lifesciences Limited</labeller>
      <ndc-id/>
      <ndc-product-code>68950-024</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-10-07</started-marketing-on>
      <ended-marketing-on>2010-11-04</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Papaverine Hydrochloride</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>66758-014</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-01</started-marketing-on>
      <ended-marketing-on>2008-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Papaverine Hydrochloride</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code>66758-015</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-01</started-marketing-on>
      <ended-marketing-on>2008-12-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 mg/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Papaverine Hydrochloride</name>
      <labeller>AMERICAN REGENT, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0517-4010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-01</started-marketing-on>
      <ended-marketing-on>2011-08-24</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Papaverine Hydrochloride</name>
      <labeller>AMERICAN REGENT, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>0517-4002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-09-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>30 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Papaverine Hydrochloride Injection USP</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00009881</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Alapav</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Albatran</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Artegodan</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Cardioverina</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Cerebid</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Cerespan</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Delapav</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Dilaves</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Dispamil</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Drapavel</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Durapav</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Dynovas</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Mesotina</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Myobid</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Optenyl</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pameion</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pamelon</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Panergon</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Papacon</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Papalease</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Papaversan</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Papital T.R.</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Paptial T.R.</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pavabid</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pavacap</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pavacen</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pavadel</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pavagen</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pavakey</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pavased</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pavatest</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Paverolan</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Paveron</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Pavnell</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Qua Bid</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Ro-Papav</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Therapav</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Vasal</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Vaso-Pav</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Papaverine Hydrochloride</name>
      <ingredients>Papaverine</ingredients>
    </mixture>
    <mixture>
      <name>Papaverine Hydrochloride</name>
      <ingredients>Papaverine</ingredients>
    </mixture>
    <mixture>
      <name>Papaverine Hydrochloride</name>
      <ingredients>Papaverine</ingredients>
    </mixture>
    <mixture>
      <name>Papaverine Hydrochloride</name>
      <ingredients>Papaverine</ingredients>
    </mixture>
    <mixture>
      <name>Papaverine Hydrochloride</name>
      <ingredients>Papaverine</ingredients>
    </mixture>
    <mixture>
      <name>Papaverine Hydrochloride</name>
      <ingredients>Papaverine</ingredients>
    </mixture>
    <mixture>
      <name>Papaverine Hydrochloride</name>
      <ingredients>Papaverine</ingredients>
    </mixture>
    <mixture>
      <name>Papaverine Hydrochloride</name>
      <ingredients>Papaverine</ingredients>
    </mixture>
    <mixture>
      <name>Papaverine Hydrochloride Injection USP</name>
      <ingredients>Papaverine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Allergy Laboratories Inc.</name>
      <url>http://www.allergylabs.com</url>
    </packager>
    <packager>
      <name>Amend</name>
      <url/>
    </packager>
    <packager>
      <name>American Regent</name>
      <url>http://www.americanregent.com</url>
    </packager>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>Ben Venue Laboratories Inc.</name>
      <url>http://www.benvenue.com</url>
    </packager>
    <packager>
      <name>C.O. Truxton Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Claris Lifesciences Inc.</name>
      <url>http://www.clarislifesciences.com</url>
    </packager>
    <packager>
      <name>Dispensing Solutions</name>
      <url>http://www.drxdispensing.com</url>
    </packager>
    <packager>
      <name>Ebewe Pharma</name>
      <url>http://www.ebewe.at</url>
    </packager>
    <packager>
      <name>Eon Labs</name>
      <url/>
    </packager>
    <packager>
      <name>Hope Pharmaceuticals</name>
      <url>http://www.hopepharm.com</url>
    </packager>
    <packager>
      <name>Kaiser Foundation Hospital</name>
      <url/>
    </packager>
    <packager>
      <name>Luitpold Pharmaceuticals Inc.</name>
      <url>http://www.luitpold.com</url>
    </packager>
    <packager>
      <name>Major Pharmaceuticals</name>
      <url>http://www.majorpharmaceuticals.com</url>
    </packager>
    <packager>
      <name>Meridian Medical Technologies Inc.</name>
      <url>http://www.meridianmeds.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Qualitest</name>
      <url>http://www.worldoftest.com</url>
    </packager>
    <packager>
      <name>Taylor Pharmaceuticals</name>
      <url/>
    </packager>
    <packager>
      <name>Time-Cap Labs</name>
      <url>http://timecaplabs.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Papaverine 60 mg/2 ml vial</description>
      <cost currency="USD">1.68</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Papaverine 150 mg capsule sa</description>
      <cost currency="USD">1.86</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Para-time 150 mg capsule sa</description>
      <cost currency="USD">0.23</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Papaverine hcl powder</description>
      <cost currency="USD">0.76</cost>
      <unit>g</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Alkaloids</category>
      <mesh-id>D000470</mesh-id>
    </category>
    <category>
      <category>Benzylisoquinolines</category>
      <mesh-id>D044182</mesh-id>
    </category>
    <category>
      <category>Cardiovascular Agents</category>
      <mesh-id>D002317</mesh-id>
    </category>
    <category>
      <category>Drugs for Functional Gastrointestinal Disorders</category>
      <mesh-id/>
    </category>
    <category>
      <category>Drugs Used in Erectile Dysfunction</category>
      <mesh-id/>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Genito Urinary System and Sex Hormones</category>
      <mesh-id/>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Hypotensive Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Isoquinolines</category>
      <mesh-id>D007546</mesh-id>
    </category>
    <category>
      <category>Miscellaneous Vasodilatating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Moderate Risk QTc-Prolonging Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Opiate Alkaloids</category>
      <mesh-id>D053610</mesh-id>
    </category>
    <category>
      <category>Papaverine and Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Phosphodiesterase Inhibitors</category>
      <mesh-id>D010726</mesh-id>
    </category>
    <category>
      <category>QTc Prolonging Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Urological Agents</category>
      <mesh-id>D064804</mesh-id>
    </category>
    <category>
      <category>Urologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Vasodilating Agents</category>
      <mesh-id>D014665</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>30 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>30 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="G04BE02">
      <level code="G04BE">Drugs used in erectile dysfunction</level>
      <level code="G04B">UROLOGICALS</level>
      <level code="G04">UROLOGICALS</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
    <atc-code code="A03AD01">
      <level code="A03AD">Papaverine and derivatives</level>
      <level code="A03A">DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS</level>
      <level code="A03">DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="G04BE52">
      <level code="G04BE">Drugs used in erectile dysfunction</level>
      <level code="G04B">UROLOGICALS</level>
      <level code="G04">UROLOGICALS</level>
      <level code="G">GENITO URINARY SYSTEM AND SEX HORMONES</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>24:12.92</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>2wey</pdb-entry>
    <pdb-entry>3iak</pdb-entry>
  </pdb-entries>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB01113.pdf?1265922740</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB09083</drugbank-id>
      <name>Ivabradine</name>
      <description>Ivabradine may increase the QTc-prolonging activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The risk or severity of orthostatic hypotension and syncope can be increased when Papaverine is combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Papaverine may increase the hypotensive activities of Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>The therapeutic efficacy of Levodopa can be decreased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>Nicorandil may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Amphetamine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>Linezolid may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>Furazolidone may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>Procaine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>Tranylcypromine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Phenelzine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>Minaprine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>Selegiline may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>Procarbazine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>Moclobemide may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>Isocarboxazid may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>Rasagiline may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>Pargyline may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>Clorgiline may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>Iproniazid may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>Nialamide may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>Safinamide may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Methylene blue may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>Hydracarbazine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Pirlindole may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Toloxatone may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>Benmoxin may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>Mebanazine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>Octamoxin may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>Pheniprazine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>Phenoxypropazine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>Pivhydrazine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>Safrazine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>Caroxazone may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>Harmaline may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>Brofaromine may increase the orthostatic hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>Butalbital may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>Pentobarbital may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>Secobarbital may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>Methohexital may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>Thiopental may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>Primidone may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>Methylphenobarbital may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>Thiamylal may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>Phenobarbital may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>Amobarbital may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>Hexobarbital may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>Barbital may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>Barbexaclone may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00204</drugbank-id>
      <name>Dofetilide</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Dofetilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00283</drugbank-id>
      <name>Clemastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Clemastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ibutilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Valproic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Terfenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Sotalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Cisapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Astemizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Trovafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Cocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Procainamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Domperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01218</drugbank-id>
      <name>Halofantrine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Halofantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Lithium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Temafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04844</drugbank-id>
      <name>Tetrabenazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Tetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Romidepsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Artemether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06708</drugbank-id>
      <name>Lumefantrine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Lumefantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Eliglustat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11730</drugbank-id>
      <name>Ribociclib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ribociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Glasdegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Deutetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13074</drugbank-id>
      <name>Macimorelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Macimorelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13725</drugbank-id>
      <name>Terodiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Terodiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Goserelin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The risk or severity of QTc prolongation can be increased when Methadone is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Clozapine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Promazine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>The risk or severity of QTc prolongation can be increased when Droperidol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Imipramine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00556</drugbank-id>
      <name>Perflutren</name>
      <description>The risk or severity of QTc prolongation can be increased when Perflutren is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Propranolol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The risk or severity of QTc prolongation can be increased when Atropine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00640</drugbank-id>
      <name>Adenosine</name>
      <description>The risk or severity of QTc prolongation can be increased when Adenosine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00748</drugbank-id>
      <name>Carbinoxamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00757</drugbank-id>
      <name>Dolasetron</name>
      <description>The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00778</drugbank-id>
      <name>Roxithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The risk or severity of QTc prolongation can be increased when Loperamide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00889</drugbank-id>
      <name>Granisetron</name>
      <description>The risk or severity of QTc prolongation can be increased when Granisetron is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00922</drugbank-id>
      <name>Levosimendan</name>
      <description>The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Fexofenadine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00976</drugbank-id>
      <name>Telithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00985</drugbank-id>
      <name>Dimenhydrinate</name>
      <description>The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The risk or severity of QTc prolongation can be increased when Primaquine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01114</drugbank-id>
      <name>Chlorpheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Chlorpheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Flecainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Levacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Clomipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01599</drugbank-id>
      <name>Probucol</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Probucol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Aceprometazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02638</drugbank-id>
      <name>Terlipressin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Terlipressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04825</drugbank-id>
      <name>Prenylamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Prenylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Lofexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04957</drugbank-id>
      <name>Azimilide</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Azimilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05223</drugbank-id>
      <name>Pracinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Pracinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05488</drugbank-id>
      <name>Technetium Tc-99m ciprofloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Technetium Tc-99m ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Garenoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06200</drugbank-id>
      <name>Tedisamil</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Tedisamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06334</drugbank-id>
      <name>Tucidinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Tucidinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Telavancin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Nemonoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08799</drugbank-id>
      <name>Antazoline</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Antazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08903</drugbank-id>
      <name>Bedaquiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Bedaquiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08980</drugbank-id>
      <name>Fendiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Fendiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Eperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Butriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Melperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Benidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09555</drugbank-id>
      <name>Dexchlorpheniramine maleate</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Dexchlorpheniramine maleate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11640</drugbank-id>
      <name>Amifampridine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Amifampridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11830</drugbank-id>
      <name>Mocetinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Mocetinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11841</drugbank-id>
      <name>Entinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Entinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Gilteritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12174</drugbank-id>
      <name>CUDC-101</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with CUDC-101.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12286</drugbank-id>
      <name>Simendan</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Simendan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12376</drugbank-id>
      <name>Ricolinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ricolinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12523</drugbank-id>
      <name>Mizolastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Mizolastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12565</drugbank-id>
      <name>Abexinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Abexinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12877</drugbank-id>
      <name>Oxatomide</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Oxatomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13261</drugbank-id>
      <name>Sitafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Sitafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Sultopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Otilonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13546</drugbank-id>
      <name>Nizofenone</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Nizofenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13652</drugbank-id>
      <name>Bunaftine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Bunaftine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13653</drugbank-id>
      <name>Lorcainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Lorcainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13679</drugbank-id>
      <name>Dexchlorpheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Dexchlorpheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Dexverapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Ivosidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The risk or severity of QTc prolongation can be increased when Octreotide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00107</drugbank-id>
      <name>Oxytocin</name>
      <description>The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Esmolol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Isradipine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Buclizine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Timolol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The risk or severity of QTc prolongation can be increased when Digoxin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00405</drugbank-id>
      <name>Dexbrompheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00427</drugbank-id>
      <name>Triprolidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00557</drugbank-id>
      <name>Hydroxyzine</name>
      <description>The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00613</drugbank-id>
      <name>Amodiaquine</name>
      <description>The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Galantamine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The risk or severity of QTc prolongation can be increased when Losartan is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Moricizine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>The risk or severity of QTc prolongation can be increased when Moexipril is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00719</drugbank-id>
      <name>Azatadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Azatadine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The risk or severity of QTc prolongation can be increased when Indapamide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The risk or severity of QTc prolongation can be increased when Propofol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00825</drugbank-id>
      <name>Levomenthol</name>
      <description>The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Amantadine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00916</drugbank-id>
      <name>Metronidazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00920</drugbank-id>
      <name>Ketotifen</name>
      <description>The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Famotidine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The risk or severity of QTc prolongation can be increased when Felbamate is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Formoterol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Felodipine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Promethazine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01071</drugbank-id>
      <name>Mequitazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01106</drugbank-id>
      <name>Levocabastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The risk or severity of QTc prolongation can be increased when Doxepin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Desipramine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>The risk or severity of QTc prolongation can be increased when Bretylium is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01176</drugbank-id>
      <name>Cyclizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>The risk or severity of QTc prolongation can be increased when Desflurane is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01228</drugbank-id>
      <name>Encainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Encainide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01426</drugbank-id>
      <name>Ajmaline</name>
      <description>The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01620</drugbank-id>
      <name>Pheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04695</drugbank-id>
      <name>Farnesyl thiopyrophosphate</name>
      <description>The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05465</drugbank-id>
      <name>Tandutinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06217</drugbank-id>
      <name>Vernakalant</name>
      <description>The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The risk or severity of QTc prolongation can be increased when Ziconotide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06468</drugbank-id>
      <name>Cariporide</name>
      <description>The risk or severity of QTc prolongation can be increased when Cariporide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06691</drugbank-id>
      <name>Mepyramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06699</drugbank-id>
      <name>Degarelix</name>
      <description>The risk or severity of QTc prolongation can be increased when Degarelix is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06719</drugbank-id>
      <name>Buserelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Buserelin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06788</drugbank-id>
      <name>Histrelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Histrelin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06825</drugbank-id>
      <name>Triptorelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07780</drugbank-id>
      <name>Farnesyl diphosphate</name>
      <description>The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07841</drugbank-id>
      <name>Geranylgeranyl diphosphate</name>
      <description>The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>The risk or severity of QTc prolongation can be increased when Fingolimod is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The risk or severity of QTc prolongation can be increased when Eribulin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08936</drugbank-id>
      <name>Chlorcyclizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Indenolol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>The risk or severity of QTc prolongation can be increased when Flumequine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09090</drugbank-id>
      <name>Pinaverium</name>
      <description>The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09229</drugbank-id>
      <name>Aranidipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aranidipine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Efonidipine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The risk or severity of QTc prolongation can be increased when Niguldipine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09488</drugbank-id>
      <name>Acrivastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11390</drugbank-id>
      <name>Coumaphos</name>
      <description>The risk or severity of QTc prolongation can be increased when Coumaphos is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11397</drugbank-id>
      <name>Dichlorvos</name>
      <description>The risk or severity of QTc prolongation can be increased when Dichlorvos is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11408</drugbank-id>
      <name>Famphur</name>
      <description>The risk or severity of QTc prolongation can be increased when Famphur is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11412</drugbank-id>
      <name>Fenthion</name>
      <description>The risk or severity of QTc prolongation can be increased when Fenthion is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11443</drugbank-id>
      <name>Orbifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11448</drugbank-id>
      <name>Phosmet</name>
      <description>The risk or severity of QTc prolongation can be increased when Phosmet is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11491</drugbank-id>
      <name>Sarafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11511</drugbank-id>
      <name>Difloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11591</drugbank-id>
      <name>Bilastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Bilastine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11614</drugbank-id>
      <name>Rupatadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11742</drugbank-id>
      <name>Ebastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Ebastine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The risk or severity of QTc prolongation can be increased when Talinolol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Anisodamine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11891</drugbank-id>
      <name>CUDC-907</name>
      <description>The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tetrahydropalmatine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12231</drugbank-id>
      <name>Temefos</name>
      <description>The risk or severity of QTc prolongation can be increased when Temefos is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12645</drugbank-id>
      <name>Givinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Givinostat is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12712</drugbank-id>
      <name>Pilsicainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13358</drugbank-id>
      <name>Cibenzoline</name>
      <description>The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13488</drugbank-id>
      <name>Bencyclane</name>
      <description>The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13555</drugbank-id>
      <name>Prajmaline</name>
      <description>The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13651</drugbank-id>
      <name>Lorajmine</name>
      <description>The risk or severity of QTc prolongation can be increased when Lorajmine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13744</drugbank-id>
      <name>Piromidic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13766</drugbank-id>
      <name>Lidoflazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13772</drugbank-id>
      <name>Rufloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13823</drugbank-id>
      <name>Pipemidic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14713</drugbank-id>
      <name>Inotersen</name>
      <description>The risk or severity of QTc prolongation can be increased when Inotersen is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The risk or severity of adverse effects can be increased when Aldesleukin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The risk or severity of adverse effects can be increased when Streptokinase is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>The risk or severity of adverse effects can be increased when Ropinirole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The risk or severity of adverse effects can be increased when Morphine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Ropivacaine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00297</drugbank-id>
      <name>Bupivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Bupivacaine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>The risk or severity of adverse effects can be increased when Tolcapone is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The risk or severity of adverse effects can be increased when Triamterene is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>The risk or severity of adverse effects can be increased when Pramipexole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>The risk or severity of adverse effects can be increased when Spironolactone is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>The risk or severity of adverse effects can be increased when Nabilone is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>The risk or severity of adverse effects can be increased when Amiloride is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>The risk or severity of adverse effects can be increased when Clofarabine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>The risk or severity of adverse effects can be increased when Amphotericin B is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>The risk or severity of adverse effects can be increased when Methazolamide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>The risk or severity of adverse effects can be increased when Tamsulosin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The risk or severity of adverse effects can be increased when Sufentanil is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>The risk or severity of adverse effects can be increased when Mannitol is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The risk or severity of adverse effects can be increased when Tretinoin is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The risk or severity of adverse effects can be increased when Conivaptan is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00883</drugbank-id>
      <name>Isosorbide dinitrate</name>
      <description>The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The risk or severity of adverse effects can be increased when Bumetanide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The risk or severity of adverse effects can be increased when Remifentanil is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The risk or severity of adverse effects can be increased when Dipyridamole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01020</drugbank-id>
      <name>Isosorbide mononitrate</name>
      <description>The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Thalidomide is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of adverse effects can be increased when Iloprost is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01143</drugbank-id>
      <name>Amifostine</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Amifostine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Diclofenamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Halothane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01282</drugbank-id>
      <name>Carbetocin</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Carbetocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01612</drugbank-id>
      <name>Amyl Nitrite</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Amyl Nitrite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04899</drugbank-id>
      <name>Nesiritide</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Nesiritide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Dapagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08822</drugbank-id>
      <name>Azilsartan medoxomil</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Azilsartan medoxomil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Isoxsuprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09112</drugbank-id>
      <name>Nitrous acid</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Nitrous acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Barnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Cilnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09279</drugbank-id>
      <name>Fimasartan</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Fimasartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>The risk or severity of adverse effects can be increased when Papaverine is combined with Sacubitril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The risk or severity of adverse effects can be increased when Verapamil is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>Papaverine may increase the hypotensive activities of Lacidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Ethanol may increase the hypotensive activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11637</drugbank-id>
      <name>Delamanid</name>
      <description>Papaverine may increase the QTc-prolonging activities of Delamanid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13967</drugbank-id>
      <name>Patent Blue</name>
      <description>The therapeutic efficacy of Papaverine can be decreased when used in combination with Patent Blue.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The therapeutic efficacy of Papaverine can be increased when used in combination with Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The therapeutic efficacy of Valsartan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>The therapeutic efficacy of Ramipril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The therapeutic efficacy of Reserpine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00212</drugbank-id>
      <name>Remikiren</name>
      <description>The therapeutic efficacy of Remikiren can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The therapeutic efficacy of Torasemide can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00217</drugbank-id>
      <name>Bethanidine</name>
      <description>The therapeutic efficacy of Bethanidine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00226</drugbank-id>
      <name>Guanadrel</name>
      <description>The therapeutic efficacy of Guanadrel can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The therapeutic efficacy of Metoprolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>The therapeutic efficacy of Olmesartan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The therapeutic efficacy of Chlorthalidone can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>The therapeutic efficacy of Nitroprusside can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The therapeutic efficacy of Atenolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00350</drugbank-id>
      <name>Minoxidil</name>
      <description>The therapeutic efficacy of Minoxidil can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The therapeutic efficacy of Nisoldipine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The therapeutic efficacy of Bendroflumethiazide can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The therapeutic efficacy of Prazosin can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>The therapeutic efficacy of Fosinopril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>The therapeutic efficacy of Trandolapril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The therapeutic efficacy of Metolazone can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The therapeutic efficacy of Lercanidipine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>The therapeutic efficacy of Benazepril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>The therapeutic efficacy of Bosentan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The therapeutic efficacy of Clonidine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The therapeutic efficacy of Enalapril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The therapeutic efficacy of Doxazosin can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The therapeutic efficacy of Labetalol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The therapeutic efficacy of Cyclothiazide can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The therapeutic efficacy of Bisoprolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00616</drugbank-id>
      <name>Candoxatril</name>
      <description>The therapeutic efficacy of Candoxatril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The therapeutic efficacy of Guanabenz can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The therapeutic efficacy of Mecamylamine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>The therapeutic efficacy of Phentolamine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>The therapeutic efficacy of Eplerenone can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>The therapeutic efficacy of Lisinopril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00727</drugbank-id>
      <name>Nitroglycerin</name>
      <description>The therapeutic efficacy of Nitroglycerin can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00765</drugbank-id>
      <name>Metyrosine</name>
      <description>The therapeutic efficacy of Metyrosine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The therapeutic efficacy of Hydroflumethiazide can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00785</drugbank-id>
      <name>Cryptenamine</name>
      <description>The therapeutic efficacy of Cryptenamine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>The therapeutic efficacy of Perindopril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The therapeutic efficacy of Candesartan cilexetil can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00797</drugbank-id>
      <name>Tolazoline</name>
      <description>The therapeutic efficacy of Tolazoline can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>The therapeutic efficacy of Fenoldopam can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>The therapeutic efficacy of Tadalafil can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The therapeutic efficacy of Alprenolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The therapeutic efficacy of Eprosartan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The therapeutic efficacy of Chlorothiazide can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>The therapeutic efficacy of Quinapril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>The therapeutic efficacy of Omapatrilat can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00925</drugbank-id>
      <name>Phenoxybenzamine</name>
      <description>The therapeutic efficacy of Phenoxybenzamine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The therapeutic efficacy of Pindolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>The therapeutic efficacy of Telmisartan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>The therapeutic efficacy of Methyldopa can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>The therapeutic efficacy of Guanfacine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The therapeutic efficacy of Trichlormethiazide can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The therapeutic efficacy of Irbesartan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01089</drugbank-id>
      <name>Deserpidine</name>
      <description>The therapeutic efficacy of Deserpidine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The therapeutic efficacy of Pentolinium can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The therapeutic efficacy of Trimethaphan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>The therapeutic efficacy of Diazoxide can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The therapeutic efficacy of Carvedilol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The therapeutic efficacy of Terazosin can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01170</drugbank-id>
      <name>Guanethidine</name>
      <description>The therapeutic efficacy of Guanethidine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>The therapeutic efficacy of Rescinnamine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The therapeutic efficacy of Captopril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The therapeutic efficacy of Nadolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The therapeutic efficacy of Epoprostenol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>The therapeutic efficacy of Hydralazine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The therapeutic efficacy of Bevantolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The therapeutic efficacy of Practolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The therapeutic efficacy of Polythiazide can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The therapeutic efficacy of Cilazapril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01347</drugbank-id>
      <name>Saprisartan</name>
      <description>The therapeutic efficacy of Saprisartan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>The therapeutic efficacy of Spirapril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The therapeutic efficacy of Penbutolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>The therapeutic efficacy of Dexpropranolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>The therapeutic efficacy of Tienilic acid can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The therapeutic efficacy of Debrisoquine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The therapeutic efficacy of Nebivolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06268</drugbank-id>
      <name>Sitaxentan</name>
      <description>The therapeutic efficacy of Sitaxentan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The therapeutic efficacy of Ambrisentan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06445</drugbank-id>
      <name>Diethylnorspermine</name>
      <description>The therapeutic efficacy of Diethylnorspermine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06762</drugbank-id>
      <name>Pinacidil</name>
      <description>The therapeutic efficacy of Pinacidil can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The therapeutic efficacy of Ferulic acid can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>The therapeutic efficacy of Temocapril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The therapeutic efficacy of Riociguat can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08932</drugbank-id>
      <name>Macitentan</name>
      <description>The therapeutic efficacy of Macitentan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08950</drugbank-id>
      <name>Indoramin</name>
      <description>The therapeutic efficacy of Indoramin can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The therapeutic efficacy of Hexamethonium can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>The therapeutic efficacy of Aliskiren can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09206</drugbank-id>
      <name>Trimazosin</name>
      <description>The therapeutic efficacy of Trimazosin can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The therapeutic efficacy of Manidipine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09242</drugbank-id>
      <name>Moxonidine</name>
      <description>The therapeutic efficacy of Moxonidine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09363</drugbank-id>
      <name>Rauwolfia serpentina root</name>
      <description>The therapeutic efficacy of Rauwolfia serpentina root can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>The therapeutic efficacy of Enalaprilat can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The therapeutic efficacy of Selexipag can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11720</drugbank-id>
      <name>Angiotensin 1-7</name>
      <description>The therapeutic efficacy of Angiotensin 1-7 can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11738</drugbank-id>
      <name>Rilmenidine</name>
      <description>The therapeutic efficacy of Rilmenidine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>The therapeutic efficacy of Imidapril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12054</drugbank-id>
      <name>BQ-123</name>
      <description>The therapeutic efficacy of BQ-123 can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The therapeutic efficacy of Naftopidil can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>The therapeutic efficacy of Landiolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>The therapeutic efficacy of Ketanserin can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12661</drugbank-id>
      <name>Urapidil</name>
      <description>The therapeutic efficacy of Urapidil can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>The therapeutic efficacy of Dihydralazine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13166</drugbank-id>
      <name>Zofenopril</name>
      <description>The therapeutic efficacy of Zofenopril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13211</drugbank-id>
      <name>Guanoxan</name>
      <description>The therapeutic efficacy of Guanoxan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13312</drugbank-id>
      <name>Delapril</name>
      <description>The therapeutic efficacy of Delapril can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13374</drugbank-id>
      <name>Vincamine</name>
      <description>The therapeutic efficacy of Vincamine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>The therapeutic efficacy of Linsidomine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13410</drugbank-id>
      <name>Guanoxabenz</name>
      <description>The therapeutic efficacy of Guanoxabenz can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13429</drugbank-id>
      <name>Tolonidine</name>
      <description>The therapeutic efficacy of Tolonidine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13435</drugbank-id>
      <name>Endralazine</name>
      <description>The therapeutic efficacy of Endralazine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The therapeutic efficacy of Esatenolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13452</drugbank-id>
      <name>Cadralazine</name>
      <description>The therapeutic efficacy of Cadralazine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>The therapeutic efficacy of Cloranolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The therapeutic efficacy of Cyclopenthiazide can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13575</drugbank-id>
      <name>Bietaserpine</name>
      <description>The therapeutic efficacy of Bietaserpine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13604</drugbank-id>
      <name>Guanazodine</name>
      <description>The therapeutic efficacy of Guanazodine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13631</drugbank-id>
      <name>Methoserpidine</name>
      <description>The therapeutic efficacy of Methoserpidine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The therapeutic efficacy of Epanolol can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13779</drugbank-id>
      <name>Guanoclor</name>
      <description>The therapeutic efficacy of Guanoclor can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>The therapeutic efficacy of Muzolimine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>The therapeutic efficacy of Xipamide can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The therapeutic efficacy of Candesartan can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The therapeutic efficacy of Dexniguldipine can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The therapeutic efficacy of Tocopherylquinone can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14125</drugbank-id>
      <name>Benazeprilat</name>
      <description>The therapeutic efficacy of Benazeprilat can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14207</drugbank-id>
      <name>Fosinoprilat</name>
      <description>The therapeutic efficacy of Fosinoprilat can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14208</drugbank-id>
      <name>Ramiprilat</name>
      <description>The therapeutic efficacy of Ramiprilat can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14213</drugbank-id>
      <name>Perindoprilat</name>
      <description>The therapeutic efficacy of Perindoprilat can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14217</drugbank-id>
      <name>Quinaprilat</name>
      <description>The therapeutic efficacy of Quinaprilat can be increased when used in combination with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The risk or severity of QTc prolongation can be increased when Trazodone is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Papaverine is combined with Entrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>Papaverine may increase the QTc-prolonging activities of Pitolisant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12825</drugbank-id>
      <name>Lefamulin</name>
      <description>Lefamulin may increase the QTc-prolonging activities of Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The risk or severity of QTc prolongation can be increased when Epirubicin is combined with Papaverine.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>4.19</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.29e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.08</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>papaverine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>339.385</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>339.147058165</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C20H21NO4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>XQYZDYMELSJDRZ-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>49.81</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>95.52</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>36.57</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>6.03</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>226 (dec) C</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>6941</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>2957</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>28241</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>4680</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508003</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C06533</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D07425</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4518</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>14754</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164745550</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>EV1</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000959</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Papaverine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL19224</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/papaverine.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/papaverine.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000487</id>
      <name>cAMP-specific 3',5'-cyclic phosphodiesterase 4B</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A6338</ref-id>
            <pubmed-id>12646997</pubmed-id>
            <citation>Xin ZC, Kim EK, Lin CS, Liu WJ, Tian L, Yuan YM, Fu J: Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.</citation>
          </article>
          <article>
            <ref-id>A6339</ref-id>
            <pubmed-id>19231363</pubmed-id>
            <citation>Zhu S, Gan Z, Li Z, Liu Y, Yang X, Deng P, Xie Y, Yu M, Liao H, Zhao Y, Zhao L, Liao F: The measurement of cyclic nucleotide phosphodiesterase 4 activities via the quantification of inorganic phosphate with malachite green. Anal Chim Acta. 2009 Mar 16;636(1):105-10. doi: 10.1016/j.aca.2009.01.035. Epub 2009 Jan 22.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q07343" source="Swiss-Prot">
        <name>cAMP-specific 3',5'-cyclic phosphodiesterase 4B</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.</specific-function>
        <gene-name>PDE4B</gene-name>
        <locus>1p31</locus>
        <cellular-location>Cytoplasmic</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.89</theoretical-pi>
        <molecular-weight>83342.695</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8781</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE4B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L20966</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>347122</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1301</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q07343</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE4B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.53</synonym>
          <synonym>DPDE4</synonym>
          <synonym>PDE32</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000972|cAMP-specific 3',5'-cyclic phosphodiesterase 4B
MKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGIDLWRGRRCCSGNLQLPPLSQRQS
ERARTPEGDGISRPTTLPLTTLPSIAITTVSQECFDVENGPSPGRSPLDPQASSSAGLVL
HATFPGHSQRRESFLYRSDSDYDLSPKAMSRNSSLPSEQHGDDLIVTPFAQVLASLRSVR
NNFTILTNLHGTSNKRSPAASQPPVSRVNPQEESYQKLAMETLEELDWCLDQLETIQTYR
SVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEYISNTFLDKQNDVEIPSPTQKDREKKK
KQQLMTQISGVKKLMHSSSLNNTSISRFGVNTENEDHLAKELEDLNKWGLNIFNVAGYSH
NRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYHSDVAYHNSLHAADVAQSTHV
LLSTPALDAVFTDLEILAAIFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHL
AVGFKLLQEEHCDIFMNLTKKQRQTLRKMVIDMVLATDMSKHMSLLADLKTMVETKKVTS
SGVLLLDNYTDRIQVLRNMVHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEI
SPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRNWYQSMIPQSP
SPPLDEQNRDCQGLMEKFQFELTLDEEDSEGPEKEGEGHSYFSSTKTLCVIDPENRDSLG
ETDIDIATEDKSPVDT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016107|cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B)
ATGAAGGAGCACGGGGGCACCTTCAGTAGCACCGGAATCAGCGGTGGTAGCGGTGACTCT
GCTATGGACAGCCTGCAGCCGCTCCAGCCTAACTACATGCCTGTGTGTTTGTTTGCAGAA
GAATCTTATCAAAAATTAGCAATGGAAACGCTGGAGGAATTAGACTGGTGTTTAGACCAG
CTAGAGACCATACAGACCTACCGGTCTGTCAGTGAGATGGCTTCTAACAAGTTCAAAAGA
ATGCTGAACCGGGAGCTGACACACCTCTCAGAGATGAGCCGATCAGGGAACCAGGTGTCT
GAATACATTTCAAATACTTTCTTAGACAAGCAGAATGATGTGGAGATCCCATCTCCTACC
CAGAAAGACAGGGAGAAAAAGAAAAAGCAGCAGCTCATGACCCAGATAAGTGGAGTGAAG
AAATTAATGCATAGTTCAAGCCTAAACAATACAAGCATCTCACGCTTTGGAGTCAACACT
GAAAATGAAGATCACCTGGCCAAGGAGCTGGAAGACCTGAACAAATGGGGTCTTAACATC
TTTAATGTGGCTGGATATTCTCACAATAGACCCCTAACATGCATCATGTATGCTATATTC
CAGGAAAGAGACCTCCTAAAGACATTCAGAATCTCATCTGACACATTTATAACCTACATG
ATGACTTTAGAAGACCATTACCATTCTGACGTGGCATATCACAACAGCCTGCACGCTGCT
GATGTAGCCCAGTCGACCCATGTTCTCCTTTCTACACCAGCATTAGACGCTGTCTTCACA
GATTTGGAGATCCTGGCTGCCATTTTTGCAGCTGCCATCCATGACGTTGATCATCCTGGA
GTCTCCAATCAGTTTCTCATCAACACAAATTCAGAACTTGCTTTGATGTATAATGATGAA
TCTGTGTTGGAAAATCATCACCTTGCTGTGGGTTTCAAACTGCTGCAAGAAGAACACTGT
GACATCTTCATGAATCTCACCAAGAAGCAGCGTCAGACACTCAGGAAGATGGTTATTGAC
ATGGTGTTAGCAACTGATATGTCTAAACATATGAGCCTGCTGGCAGACCTGAAGACAATG
GTAGAAACGAAGAAAGTTACAAGTTCAGGCGTTCTTCTCCTAGACAACTATACCGATCGC
ATTCAGGTCCTTCGCAACATGGTACACTGTGCAGACCTGAGCAACCCCACCAAGTCCTTG
GAATTGTATCGGCAATGGACAGACCGCATCATGGAGGAATTTTTCCAGCAGGGAGACAAA
GAGCGGGAGAGGGGAATGGAAATTAGCCCAATGTGTGATAAACACACAGCTTCTGTGGAA
AAATCCCAGGTTGGTTTCATCGACTACATTGTCCATCCATTGTGGGAGACATGGGCAGAT
TTGGTACAGCCTGATGCTCAGGACATTCTCGATACCTTAGAAGATAACAGGAACTGGTAT
CAGAGCATGATACCTCAAAGTCCCTCACCACCACTGGACGAGCAGAACAGGGACTGCCAG
GGTCTGATGGAGAAGTTTCAGTTTGAACTGACTCTCGATGAGGAAGATTCTGAAGGACCT
GAGAAGGAGGGAGAGGGACACAGCTATTTCAGCAGCACAAAGACGCTTTGTGTGATTGAT
CCAGAAAACAGAGATTCCCTGGGAGAGACTGACATAGACATTGCAACAGAAGACAAGTCC
CCCGTGGATACATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell periphery</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>centrosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>excitatory synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>gamma-tubulin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Z disc</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-AMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cAMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion channel binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to epinephrine stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of relaxation of cardiac muscle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neutrophil homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-gamma production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-2 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac muscle cell contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of high voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="1">
      <id>BE0000631</id>
      <name>cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16853</ref-id>
            <pubmed-id>19066855</pubmed-id>
            <citation>Weber M, Breier M, Ko D, Thangaraj N, Marzan DE, Swerdlow NR: Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology (Berl). 2009 May;203(4):723-35. doi: 10.1007/s00213-008-1419-x. Epub 2008 Dec 9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9Y233" source="Swiss-Prot">
        <name>cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A</name>
        <general-function>Metal ion binding</general-function>
        <specific-function>Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.</specific-function>
        <gene-name>PDE10A</gene-name>
        <locus>6q26</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.57</theoretical-pi>
        <molecular-weight>88411.71</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8772</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PDE10A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB020593</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4958858</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1310</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9Y233</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PDE10_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.4.17</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001258|cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A
MRIEERKSQHLTGLTDEKVKAYLSLHPQVLDEFVSESVSAETVEKWLKRKNNKSEDESAP
KEVSRYQDTNMQGVVYELNSYIEQRLDTGGDNQLLLYELSSIIKIATKADGFALYFLGEC
NNSLCIFTPPGIKEGKPRLIPAGPITQGTTVSAYVAKSRKTLLVEDILGDERFPRGTGLE
SGTRIQSVLCLPIVTAIGDLIGILELYRHWGKEAFCLSHQEVATANLAWASVAIHQVQVC
RGLAKQTELNDFLLDVSKTYFDNIVAIDSLLEHIMIYAKNLVNADRCALFQVDHKNKELY
SDLFDIGEEKEGKPVFKKTKEIRFSIEKGIAGQVARTGEVLNIPDAYADPRFNREVDLYT
GYTTRNILCMPIVSRGSVIGVVQMVNKISGSAFSKTDENNFKMFAVFCALALHCANMYHR
IRHSECIYRVTMEKLSYHSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIF
VYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTD
LERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNI
FSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMM
TACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFY
NAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016160|cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A)
ATGGAAGATGGACCTTCTAATAATGCGAGCTGCTTCCGAAGGCTGACCGAGTGCTTCCTG
AGCCCCAGTTTGACAGATGAAAAAGTGAAGGCATATCTTTCTCTTCACCCCCAGGTATTA
GATGAATTTGTATCTGAAAGTGTTAGTGCAGAGACAGTAGAGAAATGGCTGAAGAGGAAG
AACAACAAATCAGAAGATGAATCAGCTCCTAAGGAAGTCAGCAGGTACCAAGATACGAAT
ATGCAGGGAGTTGTATATGAACTAAACAGCTATATAGAACAACGGTTGGACACAGGAGGA
GACAACCAGCTACTCCTCTATGAACTGAGCAGCATCATTAAAATAGCCACAAAAGCCGAT
GGATTTGCACTGTATTTCCTTGGAGAGTGCAATAATAGCCTGTGTATATTCACGCCACCT
GGGATAAAGGAAGGAAAACCCCGCCTCATCCCTGCTGGGCCCATCACTCAGGGCACCACC
GTCTCTGCTTATGTGGCCAAGTCCAGGAAAACACTGCTAGTAGAAGACATCCTTGGAGAT
GAACGATTTCCAAGAGGTACTGGACTGGAATCAGGGACTCGTATCCAGTCTGTTCTTTGC
TTACCAATTGTCACTGCAATTGGTGACTTGATTGGTATTCTCGAGCTGTATCGGCACTGG
GGCAAAGAAGCCTTCTGTCTTAGTCACCAGGAGGTTGCAACAGCAAATCTTGCCTGGGCT
TCAGTAGCAATACATCAGGTGCAGGTATGCAGAGGCCTTGCCAAACAGACAGAATTGAAT
GACTTCCTACTCGACGTATCAAAAACATATTTTGATAACATAGTTGCAATAGATTCTCTA
CTTGAACACATAATGATATATGCAAAAAACCTGGTGAATGCCGATCGTTGTGCGCTTTTC
CAGGTGGACCATAAGAACAAGGAGTTATATTCAGACCTTTTTGATATTGGAGAGGAAAAG
GAAGGAAAACCTGTCTTCAAGAAGACCAAAGAGATAAGATTTTCAATTGAGAAAGGAATT
GCTGGCCAAGTAGCAAGAACAGGGGAAGTCCTGAACATTCCAGATGCCTATGCAGACCCA
CGCTTTAACAGAGAAGTAGACTTGTACACAGGCTACACCACGCGGAACATCCTGTGCATG
CCCATCGTCAGCCGAGGCAGCGTGATAGGTGTGGTGCAGATGGTCAACAAAATCAGTGGC
AGTGCCTTCTCTAAAACAGATGAAAACAACTTCAAAATGTTTGCCGTCTTTTGTGCTTTA
GCCTTACACTGTGCTAATATGTATCATAGAATTCGCCACTCAGAGTGCATTTACCGGGTA
ACGATGGAAAAGCTGTCCTACCATAGCATTTGTACTTCAGAAGAGTGGCAAGGTCTCATG
CAATTCACCCTTCCCGTGCGTCTCTGCAAAGAAATTGAATTATTCCACTTTGACATTGGT
CCTTTTGAAAACATGTGGCCTGGAATTTTTGTCTACATGGTTCATCGGTCCTGTGGGACA
TCCTGCTTTGAGCTTGAAAAGTTGTGTCGTTTTATTATGTCTGTGAAGAAGAACTATCGG
CGGGTTCCTTATCACAACTGGAAGCATGCGGTCACTGTAGCACACTGCATGTATGCCATA
CTTCAGAACAATCACACGCTTTTCACAGACCTTGAGCGCAAAGGACTGCTGATTGCGTGT
CTGTGTCATGACCTGGACCACAGGGGCTTCAGTAACAGCTACCTGCAGAAGTTCGACCAC
CCTCTGGCCGCTCTCTACTCCACTTCCACCATGGAGCAGCACCACTTCTCCCAGACTGTG
TCCATCCTCCAGTTGGAAGGGCACAATATCTTCTCCACTCTGAGCTCCAGTGAATATGAG
CAGGTGCTTGAGATCATCCGCAAAGCCATCATTGCCACAGACCTTGCTTTATACTTTGGA
AACAGGAAGCAGTTGGAAGAGATGTACCAGACCGGATCACTAAACCTTAATAATCAATCA
CATAGAGACCGTGTAATTGGTTTGATGATGACTGCCTGTGACCTTTGTTCTGTGACAAAA
CTGTGGCCCGTTACAAAATTGACGGCAAATGATATATATGCAGAATTCTGGGCTGAGGGT
GATGAAATGAAGAAATTGGGAATACAGCCTATTCCTATGATGGACAGAGACAAGAAGGAT
GAAGTCCCCCAAGGCCAGCTTGGGTTCTACAATGCCGTGGCCATTCCCTGCTATACAACC
CTTACCCAGATCCTCCCTCCCACGGAGCCTCTTCTGAAAGCATGCAGGGATAATCTCAGT
CAGTGGGAGAAGGTGATTCGAGGGGAGGAGACTGCAACCTGGATTTCATCCCCATCCGTG
GCTCAGAAGGCAGCTGCATCTGAAGATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01590</identifier>
            <name>GAF</name>
          </pfam>
          <pfam>
            <identifier>PF00233</identifier>
            <name>PDEase_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-GMP phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cAMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cGMP-stimulated cyclic-nucleotide phosphodiesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein kinase A signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>